Rafferty Asset Management, LLC Prothena Corp Public LTD CO Transaction History

Rafferty Asset Management, LLC

$28.9 Billion
Q3 2024

A detailed history of Rafferty Asset Management, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 62,230 shares of PRTA stock, worth $958,342. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,230

Previous 97,019 35.86%

Holding current value

$958,342

Previous $2 Million 48.0%

% of portfolio

0.0%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$16.73 - $24.79 $582,019 - $862,419	-34,789 Reduced 35.86%	62,230 $1.04 Million
Q2 2024 Aug 13, 2024	SELL	$19.54 - $26.15 $4.03 Million - $5.4 Million	-206,436 Reduced 68.03%	97,019 $2 Million
Q1 2024 May 13, 2024	BUY	$24.75 - $40.66 $2.38 Million - $3.9 Million	96,036 Added 46.3%	303,455 $7.52 Million
Q4 2023 Feb 13, 2024	BUY	$32.31 - $52.32 $1.63 Million - $2.65 Million	50,579 Added 32.25%	207,419 $7.54 Million
Q3 2023 Nov 13, 2023	BUY	$47.3 - $70.6 $1.76 Million - $2.63 Million	37,262 Added 31.16%	156,840 $7.57 Million
Q2 2023 Aug 11, 2023	SELL	$48.26 - $78.59 $1.07 Million - $1.74 Million	-22,111 Reduced 15.61%	119,578 $8.16 Million
Q1 2023 May 11, 2023	BUY	$46.97 - $58.27 $156,691 - $194,388	3,336 Added 2.41%	141,689 $6.87 Million
Q4 2022 Feb 13, 2023	BUY	$52.05 - $65.0 $1.65 Million - $2.06 Million	31,687 Added 29.71%	138,353 $8.34 Million
Q3 2022 Nov 14, 2022	BUY	$25.16 - $60.63 $633,881 - $1.53 Million	25,194 Added 30.92%	106,666 $6.47 Million
Q2 2022 Aug 12, 2022	SELL	$22.73 - $39.98 $1.41 Million - $2.48 Million	-62,075 Reduced 43.24%	81,472 $2.21 Million
Q1 2022 May 13, 2022	BUY	$30.27 - $49.22 $692,547 - $1.13 Million	22,879 Added 18.96%	143,547 $5.25 Million
Q4 2021 Feb 10, 2022	BUY	$42.11 - $73.26 $3.36 Million - $5.85 Million	79,871 Added 195.78%	120,668 $5.96 Million
Q3 2021 Nov 10, 2021	BUY	$48.2 - $78.89 $319,132 - $522,330	6,621 Added 19.37%	40,797 $2.91 Million
Q2 2021 Aug 10, 2021	SELL	$21.63 - $57.65 $149,290 - $397,900	-6,902 Reduced 16.8%	34,176 $1.76 Million
Q1 2021 May 10, 2021	BUY	$11.0 - $28.24 $451,858 - $1.16 Million	41,078 New	41,078 $1.03 Million
Q4 2020 Feb 10, 2021	SELL	$10.12 - $13.94 $232,952 - $320,884	-23,019 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.93 - $13.47 $114,214 - $154,931	11,502 Added 99.87%	23,019 $230,000
Q2 2020 Aug 07, 2020	BUY	$9.56 - $12.51 $110,102 - $144,077	11,517 New	11,517 $120,000
Q1 2020 May 15, 2020	SELL	$7.54 - $15.77 $94,114 - $196,841	-12,482 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$7.48 - $17.01 $197,965 - $450,186	-26,466 Reduced 67.95%	12,482 $198,000
Q3 2019 Nov 14, 2019	SELL	$6.89 - $10.45 $66,888 - $101,448	-9,708 Reduced 19.95%	38,948 $305,000
Q2 2019 Aug 09, 2019	SELL	$8.85 - $12.49 $55,091 - $77,750	-6,225 Reduced 11.34%	48,656 $514,000
Q1 2019 May 15, 2019	BUY	$10.32 - $14.49 $566,371 - $795,225	54,881 New	54,881 $666,000

Others Institutions Holding PRTA

# of Institutions

184

Shares Held

42.7M

Call Options Held

162K

Put Options Held

102K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $723M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.

Account

Rafferty Asset Management, LLC Prothena Corp Public LTD CO Transaction History